2. Signaling Pathways
  3. Immunology/Inflammation
  4. VAP-1
  5. VAP-1 Inhibitor

VAP-1 Inhibitor

VAP-1 Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-P99323
    Timolumab
    		Inhibitor 98.56%
    Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases.
  • HY-P99526
    Vapaliximab
    		Inhibitor
    Vapaliximab (2D10) is a monoclonal antibody against human VAP-1.
  • HY-117833
    PXS-4681A
    		Inhibitor 99.40%
    PXS-4681A is a potent, selective, irreversible and orally active semicarbazide-sensitive amine oxidase (SSAO; VAP-1) inhibitor with a Ki of 37 nM. PXS-4681A shows highly selectivity over related amine oxidases, ion channels, and seven-transmembrane domain receptors. PXS-4681A has anti-inflammatory effects.
  • HY-173596
    SNT-8370
    		Inhibitor
    SNT-8370 is an orally active inhibitor of VAP-1 (IC50: 10 nM) and myeloperoxidase (MPO) (IC50: 17 nM), with >100-1000 fold more potency for VAP-1 and MPO versus other mammalian (per)oxidases. SNT-8370 inhibits MPO-mediated LDL lipid peroxidation. SNT-8370 inhibits leukocyte infiltration in lung injury models of acute inflammation. SNT-8370 is an anti-inflammatory agent, and can be used for research of inflammatory disorders.
  • HY-157530
    VAP-1-IN-3
    		Inhibitor
    VAP-1-IN-3 (compound 136) is a potent amine oxidase vascular adhesion protein-1 (VAP-1) inhibitor, with an IC50 of 0.13 μM for VAP-1 isolated from bovine plasma. VAP-1-IN-3 can be used for the research of inflammatory.
  • HY-142444
    SSAO/VAP-1 inhibitor 1
    		Inhibitor
    SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3).